As compared with placebo, early administration of abciximab in patients with acute myocardial infarction improves coronary patency before stenting, the success rate of the stenting procedure, the rate of coronary patency at six months, left ventricular function, and clinical outcomes.

Abciximab dramatically reduces platelet aggregate size and increases the fibrin accessibility of ex vivo PRC in AMI patients. These modifications could participate in the better coronary artery patency observed with abciximab.

remission and spontaneous relapse. 1 Patients with active UC experience significant and clinically meaningful impairment across most aspects of quality of life. 2,3 The prevalence of UC in Japan has been steadily increasing from 18.2 in 1991 and 63.6 in 2005 to 121.9 per 100,000 persons in 2013; 4 about 170,000 patients were receiving treatment for UC in Japan in 2017. 5 Aminosalicylates (5-ASAs) are used as first-line therapy for induction and maintenance of remission in mild to moderately active UC; patients who do not respond to 5-ASAs are treated with corticosteroids (second-line treatment), whereas immunomodulators and biologics are used in moderately to se

for the induction and maintenance of clinical remission, and adherence to medication is an important challenge. 2 Subcutaneous (SC) administration of biologics is effective, safe, and well-tolerated. In general, SC is preferred by both patients and healthcare providers, and can be self-administered at home. 3 Currently, 3 of the 5 licensed biologics that are approved for the treatment of inflammatory bowel disease (IBD) in Japan use the SC route of administration. 4-8 The tumor necrosis factor (TNF)-α antagonists adalimumab and golimumab are approved for SC administration for the treatment of UC. 6,7 The interleukin-12/23 p40 antagonist ustekinumab is approved